VivoSeq
Other

Cigarette Smoking

0

Pipeline Programs

3

Active Trials

2

Companies Involved

Cigarette Smoking is an early-stage landscape with 0 programs across 2 companies. The most active players are Stealth BioTherapeutics Inc., Novartis.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed7 · 58%
Recruiting2 · 17%
Unknown status1 · 8%
Not yet recruiting1 · 8%
Withdrawn1 · 8%

Trial Activity

12 trials

Effects of AFQ056 and Nicotine in Reducing Cigarette Smoking
Completed·Novartis logoNovartis·Phase 1·NCT00414752·36 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)